QNRX · Quoin Pharmaceuticals, Ltd.
$4.20
-0.09 (-2.10%)
At close · Jul 28
Going-concern doubt
— flagged May 7, 2026
Substantial doubt about the company's ability to continue as a going concern.
“we must raise additional capital to fund our operations in order to continue as a going concern”View the 10-Q filed May 7, 2026
Market Cap
$303.67M
Shares
72.30M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Dr. Michael Myers | CEO | $1,507,345 |
| Denise Carter | CFO | $1,282,285 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Dr. Michael Myers | CEO | $1,406,801 |
| Denise Carter | COO | $1,211,262 |
| Gordon Dunn | CFO | $656,632 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Dr. Michael Myers | CEO | $1,255,188 |
| Denise Carter | COO | $1,070,966 |
| Gordon Dunn | CFO | $775,935 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Dr. Michael Myers | CEO | $1,966,799 |
| Denise Carter | COO | $1,805,402 |
| Gordon Dunn | CFO | $1,450,207 |